Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.

Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat

Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive Officer Chuck Baum - President, Founder & Head of Research & Development Laurie Stelzer - Chief Financial Officer Jamie Christensen - Chief Scientific Officer Ben Hickey - Chief Commercial Officer Conference Call Participants Michael Schmidt - Guggenheim Tyler Van Buren - Cowen Jonathan Miller - Evercore Ben Burnett - Stifel Andrew Berens - SVB Securities Evan Seigerman - BMO Capital Markets Yigal Nochomovitz - Citi Mike Ulz - Morgan Stanley Maury Raycroft - Jefferies Jay Olson - Oppenheimer Operator Good afternoon, and welcome to the Mirati Therapeutics Second Quarter 2022 Earnings Call. My name is Danielle, and I will be the operator for today's call.

Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q2 2022 Results - Earnings Call Transcript

Mirati (MRTX) delivered earnings and revenue surprises of 9.92% and 143.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2022 and recent corporate updates. "Mirati continues to advance the development of a broad portfolio of targeted oncology medicines," said David Meek , chief executive officer, Mirati Therapeutics, Inc. "We are progressing toward the potential launch of adagrasib for patients with previously treated non-small cell lung cancer harboring a KRASG12C mutation in the U.S. this year.

Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

SAN DIEGO , July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with recent corporate updates on August 3, 2022. During a conference call at 4:30 p.m.

Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates

Virtus LifeSci Biotech Clinical Trials ETF

Day One Biopharmaceuticals

Kezar Life Sciences Inc

Lyell Immunopharma

Repare Therapeutics

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

Biotech ETF Tops in June: 5 Stocks That Outperform

Mirati Therapeutics stock (NASDAQ: MRTX) has risen a solid 20% in a month, outperforming the broader markets with the S&P500 down 6%.

What's Next For Mirati Therapeutics Stock After A 20% Rise In A Month?

After the most aggressive growth phase, you can continue to make substantially more, if and only if, the drug later becomes a blockbuster in commercialization. After years of innovation, Mirati Therapeutics is poised to send its crown jewel (adagrasib) to the market.

Mirati Therapeutics: Growth Cycle Transition

Mirati will probably not get accelerated approval for adagrasib in 2nd line NSCLC. This will delay their program for two years.

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Alnylam Pharmaceuticals

Baxter

Biogen

Boston Scientific

Cardinal Health

Gilead Sciences

Johnson & Johnson

Karuna Therapeutics Inc

Medtronic

Natera

Roche Holding AG

Stryker

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

The company presented great data at the American Society of Clinical Oncology annual meeting.

Why Mirati Therapeutics Stock Is Skyrocketing This Week

Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.

Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib

Presentation marks first clinical dataset with a KRASG12C-inhibitor in patients with active, untreated CNS metastases SAN DIEGO , June 6, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial (IC) responses of adagrasib in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases. This is the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active and untreated CNS metastases.

New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

Mirati (MRTX) Down 35.5% Since Last Earnings Report: Can It Rebound?

Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.

Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study

Arcellx

Iovance Biotherapeutics

SpringWorks Therapeutics Inc

Zymeworks Inc

The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Clinical Oncology annual meeting.

Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

SAN DIEGO , May 26, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. Findings will be presented on June 3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, as an oral presentation during the "Lung Cancer – Non-Small Cell Metastatic" session from 2:24 to 2:36 PM ET/ 1:24 to 1:36 PM CT (Abstract #9002).

Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.

Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer

Submission follows the U.S. FDA acceptance of the adagrasib New Drug Application for the same indication   SAN DIEGO , May 19, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.  The MAA is supported by data from the registration enabling cohort of the Phase 2 KRYSTAL-1 study evaluating adagrasib 600mg BID in patients with advanced NSCLC harboring the KRASG12C mutation following prior treatment with immunotherapy and chemotherapy, either together or sequentially.

Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer

SAN DIEGO , May 16, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer (CFO) effective May 16, 2022. Laurie will report to the Company's Chief Executive Officer, David Meek.

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.

Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat

Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - CEO James Christensen - Chief Scientific Officer Ben Hickey - Chief Commercial Officer Vickie Reed - CAO Daniel Faga - Chief Commercial Officer Chuck Baum - President, Founder and Head of R&D Charles Baum - Conference Call Participants Tyler Van Buren - Cowen Neil Carnahan - Stifel Gena Wang - Barclays Jonathan Miller - Evercore Evan Seigerman - BMO Capital Markets Michael Ulz - Morgan Stanley Carly Kenselaar - Citi Andrew Berens - SVB Securities Jay Olson - Oppenheimer Silvan Tuerkcan - JMP Securities Maurice Raycroft - Jefferies Operator Good afternoon, and welcome to the Mirati Therapeutics First Quarter 2022 Earnings Call. My name is Kevin, and I will be the operator for today's call.

Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q1 2022 Results - Earnings Call Transcript

SAN DIEGO , May 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2022 and recent corporate updates. "Mirati continues to make significant progress across our pipeline, as we focus on executing our ambitious goals," said David Meek , chief executive officer, Mirati Therapeutics, Inc. "This includes working toward our first potential commercial launch in the U.S. this year with adagrasib for the treatment of patients with previously-treated KRASG12C-mutated lung cancer and advancing the adagrasib program in earlier lines of therapy and across additional tumors.

Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Full results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib in patients with pre-treated non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation Late-breaking data on adagrasib in patients with KRASG12C-mutated NSCLC with active and untreated central nervous system (CNS) metastases Company to host Virtual Investor Event on Monday, June 6, 2022 at 8 PM ET/7 PM CT to discuss highlights from ASCO 2022 SAN DIEGO , April 27, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 to 7, 2022 in Chicago, IL. "Mirati continues to develop adagrasib with the goal of having a meaningful impact on patients with lung cancer," said  Charles Baum, M.D.

Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

BioMarin Pharmaceutical

CRISPR Therapeutics

Intercept Pharma

Ionis Pharma

Novartis

Sarepta Therapeutics

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products. The post 7 Potential Biotech Stocks Buyout Targets in 2022 appeared first on InvestorPlace.

7 Potential Biotech Stocks Buyout Targets in 2022

News for Mirati Therapeutics Stock (MRTX)